美国2021年18岁及以下儿童青少年免疫规划推荐
在FDA紧急使用授权后,ACIP先后对≥16岁人群的Pfizer-BioNTech COVID-19疫苗和≥18岁人群的Moderna COVID-19疫苗作出临时推荐,并将COVID-19疫苗推荐纳入该规划。
要点
- ACIP批准2021年18岁及以下儿童青少年免疫规划
- Pfizer-BioNTech COVID-19疫苗获≥16岁人群临时推荐
- Moderna COVID-19疫苗获≥18岁人群临时推荐
核心结论
- ACIP批准2021年儿童青少年免疫规划,并将COVID-19疫苗推荐纳入其中。
主要发现
- ACIP对≥16岁人群的Pfizer-BioNTech COVID-19疫苗发出临时推荐。
- ACIP对≥18岁人群的Moderna COVID-19疫苗发出临时推荐。
关键数值与推荐
- 2021年推荐适用于18岁及以下儿童青少年。
- Pfizer-BioNTech COVID-19疫苗临时推荐适用于≥16岁人群。
- Moderna COVID-19疫苗临时推荐适用于≥18岁人群。
临床怎么用
- 按2021年ACIP儿童青少年免疫规划实施接种,并关注COVID-19疫苗临时推荐的人群范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At its October 2020 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the 2021 Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger. After Emergency Use Authorization of Pfizer-BioNTech COVID-19 vaccine by the Food and Drug Administration (FDA), ACIP issued an interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years at its December 12, 2020, meeting (1). In addition, ACIP approved an amendment to include COVID-19 vaccine recommendations in the child and adolescent immunization schedule. After Emergency Use Authorization of Moderna COVID-19 vaccine by FDA, ACIP issued an interim recommendation for use of Moderna COVID-19 vaccine in persons aged ≥18 years at its December 19, 2020, emergency meeting (2).
引用
- Wodi AP, Ault K, Hunter P, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33571172. doi:10.15585/mmwr.mm7006a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。